US unit of GC Pharma raises another $26 mn in Series A1 fundrasing

Curevo, a U.S. subsidiary of South Korea’s GC Pharma, has raised additional $26 million after $60 million Series A financing round in February to support its clinical development of adjuvanted sub-unit vaccine CRV-101 for the prevention of shingles in older adults. The financing was joined by Janus Henderson Investors, RA Capital Management, Adjuvant Capital and GC Pharma.